Abstract
Pembrolizumab is a potent, humanized, monoclonal anti-programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance and neutralize target binding, potentially reducing drug efficacy; such immunogenicity may also result in infusion reactions, anaphylaxis, and immune complex disorders. Pembrolizumab immunogenicity and its impact on exposure, safety, and efficacy was assessed in this study. Pembrolizumab immunogenicity was assessed in 3655 patients with advanced or metastatic cancer treated in 12 clinical studies. Patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, urothelial cancer, and Hodgkin lymphoma were treated with pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks. An additional study involving 496 patients with stage III melanoma treated with 200 mg adjuvant pembrolizumab every 3 weeks after complete resection was analyzed separately. Of 3655 patients, 2000 were evaluable for immunogenicity analysis, 36 (1.8%) were treatment-emerg...Continue Reading
References
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Dec 5, 2002·Current Pharmaceutical Biotechnology·E KorenA R Mire-Sluis
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Nov 26, 2008·The American Journal of Cardiology·Terje R Pedersen
Apr 29, 2009·Current Opinion in Rheumatology·Gerrit J WolbinkB A C Dijkmans
Jun 13, 2009·Current Pharmaceutical Biotechnology·Arunan Kaliyaperumal, Shuqian Jing
Mar 24, 2011·The American Journal of Gastroenterology·Henit Yanai, Stephen B Hanauer
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Aug 21, 2012·Pharmaceutical Research·Yow-Ming C WangHae-Young Ahn
Jan 10, 2014·Cancer Medicine·David F McDermott, Michael B Atkins
Apr 1, 2014·The AAPS Journal·J M SailstadJ T Wustner
Apr 26, 2014·The AAPS Journal·G ShankarS Yim
Feb 17, 2015·Drugs of Today·J McDermott, A Jimeno
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Jan 2, 2016·The AAPS Journal·Yow-Ming C WangHae Young Ahn
Jan 27, 2016·Breast Cancer Research : BCR·Rashmi VermaClive R D Carter
Jul 13, 2018·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Kiyoshi Kinoshita
Citations
May 19, 2020·Allergo Journal International·Askin GülsenUta Jappe
Oct 6, 2020·Frontiers in Immunology·Anna Vaisman-MenteshYariv Wine
Jun 18, 2020·Allergo Journal : interdisziplinäre Zeitschrift für Allergologie und Umweltmedizin : Organ der Deutschen Gesellschaft für Allergie- und Immunitätsforschung·Askin GülsenUta Jappe
Jun 20, 2020·Cancer Immunology, Immunotherapy : CII·Barry D HockMargaret J Currie
Jan 16, 2021·Drug Discovery Today·Sandeep KumarAjay Rana
Mar 12, 2021·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Fabian JunkerHenry Kao
Mar 27, 2021·Human Vaccines & Immunotherapeutics·Xinsheng LiPing Xie
Apr 9, 2021·BMC Medicine·Asger S Paludan-MüllerIsabelle Boutron
Apr 18, 2021·ESMO Open·E de GuillebonC Le Tourneau
May 1, 2021·Bioanalysis·Johannes L StantaJohn Chappell
Sep 30, 2021·Scientific Reports·S C SassonB P Fairfax